Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer
Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer
复制标题
DOI：
10.1002/cncr.23092
复制
发表时间：
2007-12-15
期刊：
影响因子：
6.2
通讯作者：
Xie, Keping
中科院分区：
文献类型：
--
作者：
Yuan, Ping;Wang, Liwei;Xie, Keping
背景。人类胰腺癌过度表达转录因子 Sp1。然而，Sp1 在胰腺癌血管生成中的作用及其作为抗血管生成治疗靶点的用途仍有待探索。使用存档的人胰腺癌标本通过免疫组织化学评估基因表达和微血管密度 (MVD) 状态：使用小干扰 RNA (siRNA) 确定 Sp1 表达改变对肿瘤生长和血管生成的影响，使用光神霉素 A (MIT) 在动物模型中评估 Sp1 靶向抗血管生成治疗人胰腺癌。 结果。 Sp1 的表达水平与 MVD 状态直接相关（P
BACKGROUND. Human pancreatic cancer over expresses the transcription factor Sp1. However, the role of Sp1 in pancreatic cancer angiogenesis and its use as target for antiangiogenic therapy remain unexplored.METHODS. Archived human pancreatic cancer specimens were used to assess gene expression and microvessel density (MVD) status by immunohistochemistry: Small-interfering RNA (siRNA) was used to determine the impact of altered Sp1 expression on tumor growth and angiogenesis, and mithramycin A (MIT) was used to evaluate Sp1-targeted antiangiogenic treatment of human pancreatic cancer in animal models.RESULTS. The expression level of Sp1 was correlated directly with the MVD status (P